• HempFusion Wellness closed the acquisition of Sagely Naturals, a women-centric CBD company, for an initial consideration of US$25 million in cash and stock payments
• The acquisition is expected to benefit both parties in various ways, including by increasing HempFusion’s revenue and providing access to Sagely’s extensive distribution footprint
• On its part, Sagely will benefit from HempFusion’s regulatory compliance, which will help in the introduction of ingestible CBD products
• HempFusion is looking forward to driving shareholder value through continued growth both domestically and internationally with its expanding family of brands

In fulfillment of a merger agreement announced in late May, Denver-based leading health and wellness company HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 800) completed the acquisition of premier women-centric CBD brand Sagely Enterprises Inc. (“Sagely Naturals”) on July 7 (https://ibn.fm/qIzoy). The purchase, which made Sagely Naturals a wholly owned subsidiary of HempFusion Wellness, is expected to benefit both parties. Boasting an extensive retail distribution footprint of 14,000+ stores in the United States, Sagely Naturals is the third most successful brand, leading CBD topicals brand, and largest women-founded CBD company in the industry. This market position is reflected in its financials for the fiscal year 2020, in which it reported net revenue of over $4.19 million. The now wholly owned subsidiary provides HempFusion with immediate distribution to up to 14,000 additional stores as well as a significant increase in revenue. In fact, when combined with the closing of APCNA Holdings LLC’s (“Apothecanna”) purchase agreement, announced May 17, HempFusion’s 2020 revenue will more than triple. Both acquisitions further offer the opportunity to expand this revenue well into the future. In an interview with Proactive (https://ibn.fm/xfGSM), HempFusion CEO Jason Mitchell, N.D., noted that while Sagely Naturals does not offer ingestible CBD products at the moment, HempFusion’s focus on being regulatorily compliant will allow it to install a completely new ingestible program for them. This will provide an opportunity to introduce ingestible CBD products in up to 14,000 stores. “So, we are going to give them near-immediate expansion into new products they haven’t had previously,” said Mitchell. HempFusion’s significant investment into regulatory compliance will help solidify Sagely Natural’s leadership position in the CBD industry. HempFusion has also included Sagely Naturals on its Novel Foods Application Dossier with the United Kingdom’s Regulatory Food Safety Agency to aid in future expansion into Europe. Additionally, as both companies have complementary product offerings that do not directly compete, the acquisition offers substantial cross-platform opportunities through each of their respective distribution channels. “Integration has been well underway over the past several weeks, and we look forward to driving shareholder value through continued growth in 2021 and 2022 both domestically and internationally with our expanding family of brands,” stated Mitchell in a press release. HempFusion closed the acquisition for an initial consideration of US$25 million, of which $2 million was paid in cash (subject to adjustment for Sagely Naturals’ cash and working capital), and the balance was satisfied by the issuance of more than 22.5 million common HempFusion shares. You can find a comprehensive description of the terms of the acquisition in the press release. In the Proactive interview, Mitchell held that M&A remains a vital part of the company’s future. Thus, the recent acquisition of Sagely Naturals “is certainly not going to be our last.” For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/CBDHF

Date: July 21-23, 2021  Virtual Event Companies and professionals from the biocompatibility, toxicology, materials engineering, and related medical fields are invited to attend the Q1 Productions’ 2nd Annual Medical Device Biocompatibility & Toxicology Risk Assessment Conference being held on July 21-23, 2021. Industry leaders and regulatory authorities will share presentations discussing compliant design and commercialization evaluation processes for medical device professionals to develop safe testing strategies. This online streaming conference is a great opportunity for you to meet and collaborate with industry professionals to ensure your products meet biological safety requirements as per the global safety standards. The event will be hosted on the dynamic Q1 Productions virtual platform that customizes the user experience by connecting attendees with their peers. Attendees will get answers to their queries while the dynamic formats ensure that participants enjoy the virtual experience. Industry leaders attending the conference will discuss safety measures and safety standards to meet the design requirements for the commercial market. The event is sponsored by WuXi AppTec Medical Device Testing, a world-class solution provider offering integrated, testing solutions that enable clients to develop strategies and safe life-changing healthcare solutions for patients and caregivers. The conference media partner is BioMedWire (“BMW”), a technology-driven communications platform. Important points to be covered at the Conference:

• Designing proper biological evaluation plans in a risk management process
• Discussion on the criteria, selection, and common measures for risk-based biological evaluation planning
• Ways to refine E&L Testing performance and efficiency
• Overcoming biocompatibility and toxicology challenges of the world markets
• Partnering with lab-testing services for better navigation, communication and to overcome the lack of uniformity
• Defining testing criteria for ethylene oxide residual testing
• Optimizing biocompatibility analysis in response to manufacturing alterations

The 2^nd Annual Medical Device Biocompatibility & Toxicology Risk assessment Conference offers insights and valuable information that allows you to test planning with in-depth analysis of regulatory requirements to ensure product reliability & patient safety. Q1 productions have a Virtual Event Guide & FAQ forum for a better user experience. The mobile app Q1 Events offers all networking experiences of the virtual platform for a seamless experience. For more information about the event, please visit https://ibn.fm/uRrPo.

• XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin
• This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy
• The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes
• XPhyto plans to capitalize on the rapid test market, projected to reach $39.1 billion by 2023

For the week starting June 27, 2021, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) began delivery of approximately 1,000 Covid-ID Lab test kits to 10 different test centers in Berlin, Germany. This move is a major commercial achievement for the company and a significant milestone for its rapid point-of-care (“POC”) diagnostic business strategy. XPhyto describes Covid-ID Lab as a “25-minute testing revolution” (https://ibn.fm/4erIO). It is specifically designed to offer reliable Covid-19 test results in under 25 minutes while offering various other benefits, including eliminating unnecessary quarantine restrictions. With this test, XPhyto also promises to increase safety in schools, medical centers and other government services and facilitating rapid airport, border and cruise ship testing to minimize travel risk. Summer is usually the high travel season. With the Covid-19 outbreak, there has been a surge in demand for reliable and rapid testing. XPhyto acknowledges this demand and plans on capitalizing on it with its Covid-ID Lab kit, the fastest PCR system in the world, according to XPhyto’s Chief Executive Officer (“CEO”), Hugh Rogers. “Our portable Covid-ID Lab is designed to be one of the fastest PCR systems in the world, while our platform is economic at low to mid-range sample volumes,” said Hugh Rogers, the CEO and director of XPhyto. “We anticipate strong and sustainable demand for our rapid and versatile PCR system and look forward to further expanding our reach,” he added (https://ibn.fm/sgnkA). XPhyto Therapeutics Corp. is a bioscience accelerator focusing on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. Its profile currently falls under three broad categories: diagnostics, drug delivery, and drug development (https://ibn.fm/GJn0r). For drug development, XPhyto focuses on four late-stage neurology therapeutics within clinical development, along with two other psychedelic medicine programs. For its drug delivery program, XPhyto has a platform technology already in place. It is designed to develop innovative, cost-effective transdermal and oral dissolvable formulations of hybrid-generic, generic and new active pharmaceutical ingredients. XPhyto’s diagnostics lead product is the rapid POC COVID-19 RT-PCR diagnostic test, which launched in Europe in April 2021. The goal for the entire program is to develop real-time ultra-low-cost infectious disease biosensors and making tests, particularly Covid-19 PCR tests, fast and affordable. With the growing requirement for PCR tests for travelling, XPhyto recognizes the tremendous potential for rapid PCR checks from a commercial standpoint. “Rapid, reliable and decentralized PCR tests are exactly what the market needs right now; precisely because incidence rates are falling and therefore sample numbers are decreasing,” noted Michael Kretzer, the CEO of Max Pharma, XPhyto’s distribution partner and pharmaceutical wholesaler (https://ibn.fm/dDOjN). “There will be areas of application where rapid, reliable, and universally recognized results are always required. Accordingly, we see a specialized and sustainable opportunity for the Covid-ID and anticipate a steep order volume uptake in the near future,” he added. Covid-ID Lab represents a significant shift from conventional PCR testing models. Typically, samples collected are shipped to large centralized and automated labs for processing. This has been known to not only take time but also be expensive (https://ibn.fm/4RMhK). XPhyto seeks to address this with its decentralized testing model. It projects that it will yield faster results, more versatile test center options and, most importantly, cost-effectiveness at lower testing volumes. The deployment of the 1000 Covid-ID Lab test kits marks the start of a short trial period for integrating and evaluating XPhyto’s new PCR test system. The entire process is designed so that sample processing will occur directly at the sample collection site. The data collected will allow the company to launch the product successfully in other locations across Europe. XPhyto continues to innovate and grow its three key sectors. With the deployment of its Covid-ID Lab, the company aims at capitalizing on the rapid test market that is projected to reach $39.1 billion by 2023, representing a compound annual growth rate (“CAGR”) of 8.9% between 2021 and 2023. The two other aspects of XPhyto’s diagnostic pipeline include the Peptide biosensor for infectious diseases and the Peptide biosensor for oral health, both of which are still in their design and development stages. For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• Avricore Health Inc. is a pharmacy solutions provider that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues
• The company’s wholly owned subsidiary, HealthTab, offers fast, accurate and cost-effective point-of-care screening
• Its current test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR); HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19
• The company leverages strategic partnerships with notable names in the diagnostic space, including Abbott Rapid Diagnostics, to offer high quality, low-cost screening tests
• In June 2021, Avricore announced its master agreement to pilot its HealthTab platform for diabetes management in select Shoppers Drug Mart pharmacies
• Avricore’s ultimate aim is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacy

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab(TM) (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies. HealthTab HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform. The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (“RWD”) sets and third-party app integration through API. Agreement with Shoppers Drug Mart In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2(TM) analyzers provided by Abbott Rapid Diagnostics. Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes. Near Term Goals Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage. Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies. Market Outlook In 2020, the global point-of-care testing (“POCT”) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (“CAGR”) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19. The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection. Management Team Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion. Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs. David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia. Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia. Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Lexaria Bioscience is a drug bioavailability platform developer intent on providing an effective oral administration alternative to smoking that duplicates the rapid assimilation benefits of inhalation without the lung-harmful effects
• The company’s DehydraTECH IP is being evaluated for concentration levels, tolerability and ability to transform partner drugs to oral solutions without incidentally creating new molecular entities
• Lexaria announced voluntary delisting from the Canadian Securities Exchange this month in order to focus its resources more effectively on its Nasdaq listing
• The company’s leadership recently interacted with investors in the Life Sciences Investor Forum virtual conference series and the company’s annual meeting

The apex of the summer season is a time for movie studios to roll out their most-anticipated productions, TV fans and gamers to pore over lists of new releases and young sun-seekers to enjoy fun business promotions ranging from amusement park activities to themed food events before the looming return to school. As the COVID-19 pandemic continues to occupy headlines worldwide, pharmaceutical companies are working toward announcements of a more sober nature, introducing advances toward potential solutions for the global health crisis as well as other medical concerns lacking such a large level of publicity at this moment in history. Drug bioavailability innovator Lexaria Bioscience (NASDAQ: LEXX) recently announced expectations that its R&D program will soon yield reporting on a number of key programs partnering Lexaria’s IP with pandemic-target antivirals, NSAIDs and other products studying hypertension and oral nicotine (https://ibn.fm/Y2SZN). To further the company’s efforts to focus its capital and other resources on Lexaria’s applied research and development programs, the global innovator in drug delivery platforms announced earlier this month that it had chosen to delist its common shares from the Canadian Securities Exchange (CSE ticker LXX) effective July 8, at which point the company’s shares will only trade on the Nasdaq Capital Markets. “Since Lexaria’s shares began trading on the Nasdaq in January 2021, the overwhelming majority of trading has moved to Nasdaq, providing more liquidity for shareholders than ever before experienced. The Company expects to realize savings in fees and managerial time and effort that were required to maintain a dual listing,” the announcement states (https://ibn.fm/H4CXz). The announcement adds that securities listed with Nasdaq are designated as a “qualified investment” to maintain Lexaria shares in Canadian Registered Savings Plans, including RRSP, RESP, RRIF, RDSP and TFSA. Lexaria’s DehydraTECH IP is designed to convert drugs into a powdered or liquid form that will make them orally ingestible with quick absorption and efficacy comparable to the bioavailability experienced by inhaling smoked drugs, but without the harmful lung effects smoking can produce. The key R&D programs nearing reporting stage this month are evaluating DehydraTECH’s tolerability and pharmacokinetics (also known as “PK,” or its chemical life cycle from administration to elimination from the body) within animal test subjects; assessing DehydraTECH’s ability to avoid altering the partner drug to such a degree that it would create covalently-bonded new molecular entities (“NMEs”) that would trigger additional regulatory concerns; and, much-anticipated results related to its first human clinical study on utilizing DehydraTECH-processed CBD for purposes of treating hypertension . Lexaria participated in June’s Life Sciences Investor Forum virtual conference series, which facilitates global investor audience interaction with presenting companies. The company’s presentation is now available for on-demand viewing at the conference’s website for a limited time (https://ibn.fm/iwP3Y). Lexaria also recently conducted its annual meeting with investors, and has announced the results of voting on board directors, the company’s auditors, and a pair of proposals related to share issuance and other corporate decisions (https://ibn.fm/vAWvw). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Zero-emissions electric tractor manufacturer Solectrac recently announced that agriculture and construction industry veteran Mani Iyer will succeed the company’s founder as CEO as Solectrac enters an anticipated period of new growth
• Solectrac is a subsidiary of clean energy-focused company Ideanomics Inc., which announced its 100 percent acquisition of the EV tractor manufacturer and distributor last month

The electric vehicle (“EV”) market continues its push toward maturity as many of the world’s governments struggle to enact systemic change to their energy policies as a response to persistent concerns about the global climate (https://ibn.fm/9iw8G). New York-based EV company Ideanomics (NASDAQ: IDEX) is helping to advance clean energy enterprises in response to the established need for solutions. Multinational accounting and professional services network Ernst & Young Global Limited (“EY”) has predicted EVs will become more popular than internal combustion engine (“ICE”) gas-powered vehicles by 2033 in the United States, Europe and China, just over a decade from now, while more conservative forecasts tack another five years onto the timeline but otherwise agree about the ascendance of EVs in the world’s auto industries, according to an analysis published July 6 by InsideEVs (https://ibn.fm/2kBxQ). Ideanomics boosted its stake in Solectrac to 100 percent last month, acknowledging the importance of EV technology not only to transportation but to the agricultural industry as well (https://ibn.fm/450Tb). As such, Solectrac is advancing to a leading position in what is currently a limited field of competition within the specialized EV sector with a product that is fully scalable and able to generate revenue. On July 1, the company announced Solectrac’s new CEO will be agriculture and construction industry veteran Mani Iyer, with expectations that his experience in international equipment sales and marketing, business strategy and development, channel development, supply chain management, product support and service, manufacturing, and quality assurance will help the company build manufacturing and distribution scale for its EV tractor products (https://ibn.fm/Vq5Fb). Iyer is building on a record of delivering distribution and supply chain innovation that has granted him a reputation for proven results within the tractor industry and beyond. “Through a relentless focus on reducing the total cost of ownership, creating a category-leading portfolio of best-in-class tractors and accessories, and driving the buildout of a world-class dealer network, Solectrac will be poised for rapid market share and revenue expansion,” Iyer stated. “We will also leverage lending and financial services from Ideanomics Capital to jumpstart sales through innovative financing and promotions in both our online and dealer channels for a simple and seamless buying experience.” Solectrac’s founder and former CEO Steve Heckeroth led the search for his successor and will continue with the company as chairman of the board, according to the announcement. “Mani brings a wealth of experience in supply chain and channel distribution, along with a stellar network of dealer relationships, all of which will be invaluable to the growth of the company as we continue to lead the zero-emission, regenerative farming movement,” he stated. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• FingerMotion’s subsidiary Xunlian Tianxia Technology entered into an agreement with Happy Life Insurance to create an innovative, data-driven insurance business model
• The model aims to develop new insurance products that can address real consumers’ needs by combining Xunlian’s data mining and customer profiling experience with Happy Life’s insurance expertise
• The new collaboration follows a similar announcement earlier this year in which FingerMotion partnered with Pacific Life Re-Insurance
• FingerMotion expects multiple contracts relating to its insurtech products before the end of calendar 2021

New technologies such as big data, blockchain, the Internet of Things (“IoT”), artificial intelligence (“AI”), and cloud computing have been continuously going mainstream. They have even been integrated into the insurance industry, instigating reforms and making it more effective and widespread. KPMG China’s Head of Insurance Walkman Lee acknowledges that insurtech is reshaping the operational ecosystem, helping to address weaknesses, driving high-quality development, and making insurance available to all (https://ibn.fm/fAh2q). However, implementing programs, which synergistically combine insurance expertise and technological innovations to create integrative value that benefits both the consumer and the insurance companies, has been challenging. This is the problem FingerMotion (OTCQX: FNGR), an evolving technology company, aims to solve through its subsidiary Xunlian Tianxia Technology. Recently, Xunlian Tianxia Technology, a leading cloud service provider in China, and Happy Life Insurance, a life insurance provider in China, entered into an agreement to create an innovative, data-powered insurance business model that will deliver a bevy of digital insurance solutions for customers (https://ibn.fm/1Fn5E). The collaboration will draw from both parties’ expertise and experiences in their respective areas of focus, which, though different, intersect at their reliance on innovative technologies. One of the pioneers in exploring innovative technologies such as blockchain and AI, Xunlian Tianxia Technology has used superior technology to serve an extensive roster of institutional clients and consumers in China. As a result, in addition to amassing abundant customer resources, it has enhanced business efficiency, corporate marketing capabilities, and communication experienced geared towards greater business value creation. The company also has extensive business development experience in big data mining and detailed customer profiling On the other hand, Happy Life Insurance is keen on cultivating an ecosystem that promotes tech-driven enhancements in distribution and operational efficiency while developing customer-focused systems and processes to improve the general insurance experience for customers. The company is also intent on collaborating with partners. As one such partnership, the newly announced collaboration is mutually beneficial. The alliance will combine Happy Life’s understanding of the types of insurance that resonates with consumers and Xunlian’s extensive experience in big data mining and customer profiling. The result will be an integration of big data into insurance products, thus enabling both parties to create and distribute insurance solutions that match consumer profiles, provide increased flexibility, and allow consumers to save costs. Additionally, it is expected to bring about underwriting efficiencies that will trickle down to the companies’ bottom line. “In order to make this collaboration work, we have to dig deep to design insurance products that can address real consumer needs,” commented FingerMotion CEO Martin Shen. “Our teams are uniquely qualified to create new insurance products that push the envelope of what is possible.” In January 2021, FingerMotion announced a landmark agreement with Pacific Life Re-insurance in which it would apply new insights generated from its predictive model to the insurance industry (https://ibn.fm/rAyZI). In what Shen described as an opportunity to create a new business model that augments the insurance value chain and results in more efficiency, the agreement appears to have set the foundation for similar partnerships within the insurance industry. With the company anticipating multiple other contracts relating to its insurtech products before the year’s end, the stage looks set for FingerMotion, its subsidiary, and partners to improve the insurance value chain and create products that can address real consumer needs. Or, more concisely, to push the envelope. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Company files provisional patent for EdManage Analytics Platform with US patent office
• EdManage carefully aggregates individual parts into new entity that provides insightful, useful and actionable information
• Emaginos believes its EdManage system has potential to make a profound impact on education

Emaginos, a REG-A public company (please see website if interested in investing) in the business of transforming K-12 public education, has filed a patent for its EdManage Analytics Platform (https://ibn.fm/EzYJ5). Emaginos announced earlier this month that it had filed a provisional patent application, titled “Education Analytics Platform,” with the United States Patent and Trademark Office for its proprietary analytics platform designed to aggregate and analyze a school district’s data to deliver actionable information to users throughout the system. “Aristotle is frequently quoted as saying, ‘The whole is greater than the sum of the parts’ — with the clarification that this is only true when the whole emerges as something other than a heap of parts,” said Emaginos president Allan Jones. “If the parts are deliberately combined systematically into some new entity, then through synergy, the new entity emerges. “Calling today’s K-12 public education a ‘system’ is a misnomer,” he continued. “It could better be described as a heap of components trying to collaborate in delivering quality education to the students. The components include everything from student handheld devices to the computer or cloud servers where the applications reside, including the network on which everything communicates. The parts do not magically morph into a smoothly functioning education system. They remain a heap of parts through which educators dig as they try to facilitate learning. For each of the parts, years of usage have evolved them individually to perform their isolated tasks. End of story — until now.” The EdManage analytics platform carefully aggregates these individual parts, morphing them into a new entity that is truly greater — think more insightful, useful and actionable — than the sum of its parts. Emaginos believes its EdManage system has potential to make a profound impact on education. The system integrates all of the devices and applications within a school system that traditionally operate independently, creating cohesive information that can be carefully evaluated. This coming together hasn’t been possible before in the educational space because all the components came from a variety of places and operated independently, using application program interfaces (APIs) and other standards to communicate when needed. EdManage changes this approach, resulting in information that can lead to school district and leaders making important decisions that could transform the way education looks. Emaginos is confident that a well-designed and implemented analytics platform that sheds light on information that previously wasn’t available provides exciting opportunities for those interested in building an educational system that delivers the kind of education that can transform lives. “There is a need to provide and implement such a platform to enhance the ability to efficiently educate children while comprehensively providing an integrated platform to coordinate all operational efforts of increasingly complex school districts,” the company states. EdManage is a key component of the Emaginos Discovery Learning System, enabling constant opportunities to do and understand. The EdManage analytics platform aggregates and analyzes all of a district’s data and then provides previously unattainable actionable information for optimizing every aspect of the district’s operations. For more information about Emaginos and its proprietary analytics platform, as well as to learn about investment and shareholder opportunities, visit www.Emaginos.com NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos

• Jazz Pharmaceuticals’ acquisition of GW Pharma for $7.2 billion in February 2021 shows the massive potential of the drug development industry from naturally-derived compounds
• Tryp Therapeutics is following in the footsteps of GW with its innovative drug pipeline and the development of psilocybin-based compounds for the treatment of diseases with high unmet medical needs
• It is one of only a handful of companies moving into Phase 2a clinical trials with a psychedelic compound, and seeks to duplicate the success of GW

As of 2020, the global biotech sector was valued at $753 billion. It is further projected to grow at a compound annual growth rate of 16% between 2021 and 2028 (https://ibn.fm/zidIe). Two key sub-sectors show great promise:  cannabis and psychedelics, which both have significant potential with drug development activities. This value is further evidenced by the recent growth in venture capital investment in these industries and the success of the industry pioneer, GW Pharma, which was acquired by Jazz Pharmaceuticals plc (NASDAQ: JAZZ) for $7.2 billion in February 2021 (https://ibn.fm/ia4Du). Between 2019 and 2020, venture capital investment in this sector grew from $100 million to $346 million. So far in 2021, the sector has raised over $329 million. Additionally, Jazz Pharmaceutical’s acquisition of GW Pharma serves as validation of a sector that has tremendous potential for growth while addressing conditions with few existing treatment options (https://ibn.fm/MwYsX). Like GW Pharma’s successful approach with cannabis-derived compounds, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is driving significant innovation with its drug development pipeline using psilocybin-based compounds for the treatment of diseases with high unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program is focused on developing treatments for chronic pain indications including fibromyalgia, phantom limb pain, and complex regional pain syndrome.  The company is also preparing to initiate a Phase 2a clinical trial for eating disorders such as binge eating and hypothalamic obesity. With the growing popularity and proliferation of psychedelics, many companies are pursuing therapeutic indications with the compounds. However, very few have initiated Phase 2a studies. Tryp Therapeutics is one of the few companies that will have initiated multiple Phase 2a clinical studies by the end of 2021. Looking back at GW Pharma and the strides it made, it is easy to see the similarities between the two enterprises, based upon their strategies and the paths taken so far. GW clearly foresaw the huge potential value of drug development for cannabis-derived compounds.  Tryp is pursuing a similar path, but with psychedelic-derived compounds. The investment from GW paid off with the FDA approval of the first-ever cannabis-based drug in June 2018 (https://ibn.fm/36UME). Its premier product, Epidiolex (cannabidiol), designed for controlling seizures in rare forms of epilepsy, generated over $500 million in sales in 2020 alone. Experts project that it could surpass $1 billion soon (https://ibn.fm/K5axF). GW’s FDA drug approval marked a huge milestone, not just for GW Pharma but also for other companies in the evolving biotech space. Tryp is capitalizing on this momentum and the path outlined by GW to create its own success with its PFN program. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• SMEs account for about 60% of China’s production GDP
• However, they have a relatively low adoption of SaaS and automation tools
• Infobird, through innovation and education, is trying to rectify this issue
• By targeting these SMEs, it will be impacting the entire Chinese SaaS market, positioning it as a global leader

As of 2019, the Chinese software-as-a-service SaaS market was estimated between $3.7 billion and $6 billion in value (https://ibn.fm/NBymg). That was just 6% less than the total value of the global SaaS market. This is great for the country. However, when compared to other nations such as the United States, the United Kingdom, Germany, Japan, South Korea, and India, it could use a little more adoption of SaaS and enjoy the benefits and growth that come with it. Infobird (NASDAQ: IFDB) seeks to address that, mainly through innovation and a marketing strategy meant to grow its market share and the SaaS industry in China. Infobird has constantly been pushing the envelope regarding the development and launch of the next generation SaaS in China. By targeting leading industries and specific enterprises within these industries, the company is slowly but surely proving what it can do and its potential for taking over both the Chinese and the global markets (https://ibn.fm/qqhHQ). Currently, small and medium-sized enterprises (“SMEs”) account for about 60% of China’s production GDP. However, their rate of adoption of automation and SaaS is relatively low. This sector’s potential for adopting SaaS far exceeds most markets worldwide, including but not limited to the United States, India, Japan, Germany, and the United Kingdom. Despite its potential, this market is relatively untapped, and Infobird is pushing to fix the situation, firstly educating these organizations and the entrepreneurs therein on the benefits of SaaS, and innovating to suit their needs and wants. Infobird is a SaaS provider focusing on artificial intelligence (“AI”)-powered customer engagement solutions for the Chinese market. Its tech infrastructure is founded on cloud computing, machine learning, patented Voice over Internet Protocol (“VoIP”) application technologies, and AI (https://ibn.fm/EylhH). Since its inception back in October 2001, the company has stayed committed to empowering clients with solutions specifically designed for the issues they face, all while increasing their revenue, reducing costs, enhancing service quality, and overall customer satisfaction. With its focus on SMEs, Infobird is trying to grow China into a leading SaaS market globally. By constantly innovating and tailoring its products and services to the customers, the company is slowly demystifying software and automation in business processes. With its flagship customer engagement software, Infobird can show customers the value of AI customer engagement, along with AI salesforce management. The product, which over 358 customers currently use in industries including health care, education, consumer products, public services, and finance, is proving valuable and essential to improving customer satisfaction and the overall efficiency of an organization’s operations. As such, Infobird is slowly showing its consumers in the Chinese market the value of leveraging its tools and the benefits that come with it. As it currently stands, Infobird’s role is far bigger than the company itself. Through its efforts to innovate and push its products in the market, it is aiding in growing SaaS adoption within China. More importantly, it allows China to grow and achieve its potential to become a global leader in the SaaS market. For more information, visit the company’s website at www.Infobird.com/en/index.html. NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD